Effects of obesity and ancillary variables (dialysis time, drug, albumin, and fatty acid concentrations) on theophylline serum protein binding
✍ Scribed by Linyee Shum; Dr. William J. Jusko
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 638 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
✦ Synopsis
The effect of obesity on the serum protein binding of theophylline was investigated in man and rat along with other ancillary variables such as dialysis time, theophylline concentration, albumin concentration, and fatty acid type and concentration. The per cent binding of theophylline first increased with dialysis time, reached equilibrium over 2 to 6h, then diminished. This decrease was not due to instability of theophylline. Theophylline binding was linear over a concentration range of 15 to 150pg ml-'. A similar degree of binding was found in normal humans (44.4 f 1.0%) and rats (41.5 ? 05%). The binding ratio (bound/free) of theophylline was proportional to the albumin concentration (1 to 5%) and yielded a binding parameter (NK) of 1.47 x M-'. Over a normal physiological range, individual and mixed fatty acids had minimal effects on theophylline binding to albumin. However, binding significantly decreased as fatty acid (FFA) concentrations increased. The magnitude of the effect appeared to parallel the carbon chain number of the fatty acid. Theophylline binding in obese subjects decreased to a mean (SD) of 35.8 f 8.0 per cent compared to 43.0 ?r 6 1 per cent in normal subjects (p < 0.05). Similar decreases were found in normal versus obese rats and in the saliva: serum ratio following theophylline administratin to normal and obese human subjects. Obesity causes a moderate decrease in serum binding of theophylline which may be attributed to increased FFA rather than in vitro artifacts. KEY WORDS Theophylline binding Obesity Free fatty acids INTRODUCTION Obesity is associated with abnormal serum lipid chemistry.' Benedek et a1.'
showed that because of an increase of alpha]-acid-glycoprotein (AAG) in serum, obese subjects had higher serum binding of propranolol. However, serum